The body’s chemical messengers, which various cells use to communicate with each other. The cytokines known as tumor necrosis factor (TNF), interleukin-6 (IL-6), and interleukin-1 (IL-1) have all been implicated in the inflammation associated with rheumatoid arthritis and related diseases. Fortunately, drug manufacturers have designed drugs specifically to block the actions of these cytokines: Adalimumab (Humira), etanercept (Enbrel), infliximab (Remicade), and golimumab (Simponi) all fight inflammation by blocking the action of TNF; tocilizumab (Actemra) inhibits IL-6; and anakinra (Kineret) blocks IL-1.

Robert S. Dinsmoor is a medical writer and editor based in Massachusetts.

Learn more about the health and medical experts who who provide you with the cutting-edge resources, tools, news, and more on Pain-Free Living.
About Our Experts >>

Statements and opinions expressed on this Web site are those of the authors and not necessarily those of the publishers or advertisers. The information provided on this Web site should not be construed as medical instruction. Consult appropriate health-care professionals before taking action based on this information.